A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximabSang Gyu Lee, Kang‐Yell Choi|Experimental & Molecular Medicine|2018Cited by 28